

# WHO Expert Committee on Biological Standardization

---

Sixty-seventh report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order on line: [www.who.int/bookorders](http://www.who.int/bookorders)).

W H O T e c h n i c a l R e p o r t S e r i e s  
1 0 0 4

# WHO Expert Committee on Biological Standardization

---

Sixty-seventh report

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Biological Standardization, sixty-seventh report

(WHO technical report series ; no. 1004)

ISBN 978-92-4-121013-3

ISBN (PDF) 978-92-4-069645-7

ISSN 0512-3054

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Expert Committee on Biological Standardization, sixty-seventh report. Geneva: World Health Organization; 2017 (WHO technical report series ; no. 1004). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Printed in Italy

# Contents

<b>Abbreviations</b>	xv
<b>1. Introduction</b>	1
<b>2. General</b>	4
2.1 Current directions	4
2.1.1 Strategic directions in biological standardization: WHO priorities	4
2.1.2 Vaccines and biotherapeutics: recent and planned activities in biological standardization	5
2.1.3 Blood products and in vitro diagnostics: recent and planned activities in biological standardization	8
2.2 Reports	10
2.2.1 Report from the WHO Blood Regulators Network	10
2.2.2 Report from the WHO network of collaborating centres on standardization and regulatory evaluation of vaccines	12
2.2.3 Report from the WHO network of collaborating centres for blood products and in vitro diagnostics	13
2.3 Feedback from custodian laboratories	14
2.3.1 Developments and scientific issues highlighted by custodians of WHO biological reference preparations	14
2.4 Cross-cutting activities of other WHO committees and groups	20
2.4.1 WHO Global Model Regulatory Framework for Medical Devices including IVD medical devices	20
2.4.2 Report of a WHO ad hoc consultation on International Nonproprietary Names for biological substances	21
2.4.3 Monographs on capreomycin sulfate and capreomycin for injection in <i>The International Pharmacopoeia</i>	22
2.4.4 Yellow fever vaccine shortages and outbreak response	24
2.4.5 Vaccines for public health emergencies	25
<b>3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological substances</b>	28
3.1 Biotherapeutics other than blood products	28
3.1.1 Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs)	28
3.2 Blood products and related substances	29
3.2.1 Blood regulation activities	29
3.2.2 Africa Society for Blood Transfusion	30
3.2.3 Guidelines on management of blood and blood components as essential medicines	32
3.2.4 Guidelines on estimation of residual risk of HIV, HBV or HCV infections via cellular blood components and plasma	33
3.2.5 WHO assessment of antivenoms	34
3.2.6 Guidelines for the production, control and regulation of snake antivenom immunoglobulins	35
3.3 Cellular and gene therapies	36
3.3.1 Regulation of cell therapy products	36

3.3.2	Reference preparations for gene therapy products	38
3.4	In vitro diagnostics	40
3.4.1	Preparation of secondary reference materials for in vitro diagnostic assays designed for infectious disease nucleic acid or antigen detection: calibration to WHO International Standards	40
3.4.2	WHO prequalification of in vitro diagnostic devices	41
3.5	Vaccines and related substances	43
3.5.1	Revision of WHO Guidelines for the safe production and quality control of inactivated poliomyelitis vaccines manufactured from wild polioviruses	43
3.5.2	Guidelines on regulatory preparedness for provision of marketing authorization of human pandemic influenza vaccines in non-vaccine-producing countries	44
3.5.3	Labelling information of inactivated influenza vaccines for use in pregnant women	46
3.5.4	Revision of the WHO Guidelines on clinical evaluation of vaccines: regulatory expectations	47
3.5.5	Human challenge trials for vaccine development: regulatory considerations	48
3.5.6	Guidelines on the quality, safety and efficacy of Ebola vaccines	49
<b>4.</b>	<b>International reference materials – biotherapeutics other than blood products</b>	<b>51</b>
4.1	Proposed new projects and updates – biotherapeutics other than blood products	51
4.1.1	Proposed Second WHO International Standard for parathyroid hormone 1-34 (recombinant, human)	51
4.1.2	Proposed First WHO international standards for vascular endothelial growth factor antagonists	52
4.1.3	Proposed First WHO international standards (or reference panels) for antibodies for use in immunogenicity assessments of biotherapeutic products	53
4.1.4	Proposed First WHO international standards (or reference reagents) for monoclonal antibodies to the ErbB/HER receptor family	54
<b>5.</b>	<b>International reference materials – blood products and related substances</b>	<b>56</b>
5.1	WHO International Standards and Reference Reagents – blood products and related substances	56
5.1.1	Second WHO International Standard for anacrod	56
5.1.2	First WHO Reference Reagent for batroxobin	57
5.1.3	Second WHO International Standard for blood coagulation factor XI (plasma, human)	57
5.1.4	Fifth WHO International Standard for thromboplastin (recombinant, human, plain)	58
5.1.5	Fifth WHO International Standard for thromboplastin (rabbit, plain)	59
5.2	Proposed new projects and updates – blood products and related substances	60
5.2.1	Proposed Second WHO International Standard for blood coagulation factor V (plasma, human)	60
5.2.2	Proposed First WHO International Standard for blood coagulation factor XII (plasma, human)	60
5.2.3	Proposed assignment of factor XIII-B subunit (total and free) values to the First WHO International Standard for factor XIII plasma	61

5.2.4	Proposed First WHO International Standard for thrombin-activatable fibrinolysis inhibitor (plasma, human)	62
5.2.5	Proposed Third WHO International Standard for anti-D immunoglobulin	63
5.2.6	Update on the use of WHO reference materials in assays to detect activated blood coagulation factor XI in immunoglobulins	63
<b>6.</b>	<b>International reference materials – cellular and gene therapies</b>	<b>65</b>
6.1	Proposed new projects and updates – cellular and gene therapy	65
6.1.1	Proposed First WHO International Standard for lentiviral vector copy number quantitation	65
<b>7.</b>	<b>International reference materials – in vitro diagnostics</b>	<b>67</b>
7.1	WHO International Standards and Reference Reagents – in vitro diagnostics	67
7.1.1	First WHO International Standard for Zika virus RNA for NAT-based assays	67
7.1.2	First WHO Reference Panel for Ebola virus VP40 antigen	68
7.1.3	First WHO reference reagents for dengue virus serotypes 1–4 RNA for NAT-based assays	69
7.1.4	Fourth WHO International Standard for hepatitis B virus DNA for NAT-based assays	70
7.1.5	Fourth WHO International Standard for prolactin (pituitary, human)	72
7.1.6	First WHO Reference Panel for the Janus kinase 2 V617F gene mutation	73
7.2	Proposed new projects and updates – in vitro diagnostics	74
7.2.1	Update on the proposed First WHO International Standard for Ebola virus antibodies (plasma, human)	74
7.2.2	Proposed First WHO International Standard for Zika virus antibodies (immunoglobulin G and immunoglobulin M) (human)	75
7.2.3	Proposed First WHO International Standard for chikungunya virus antibodies (immunoglobulin G and immunoglobulin M) (human)	75
7.2.4	Proposed Second WHO International Standard for syphilitic plasma (immunoglobulin G and immunoglobulin M) (human)	76
7.2.5	Proposed Second WHO International Standard for syphilitic plasma (immunoglobulin G) (human)	77
7.2.6	Proposed Second WHO International Standard for human immunodeficiency virus type 2 RNA for NAT-based assays	77
7.2.7	Proposed First WHO International Standard for respiratory syncytial virus RNA for NAT-based assays	78
7.2.8	Proposed First WHO International Standard for influenza virus type A RNA for NAT-based assays	79
7.2.9	Proposed First WHO International Standard for influenza virus type B RNA for NAT-based assays	79
7.2.10	Proposed First WHO Reference Panel for the BRAF V600E gene mutation	79
7.2.11	Proposed First WHO Reference Panel for ErbB2 copy number and mRNA expression	80
<b>8.</b>	<b>International reference materials – vaccines and related substances</b>	<b>81</b>
8.1	Proposed new projects and updates – vaccines and related substances	81
8.1.1	Proposed First WHO International Standard for Sabin inactivated poliomyelitis vaccine	81
8.1.2	Proposed First WHO international standards for Group B streptococcus (polysaccharide and antiserum)	81

8.1.3	Proposed Second WHO International Standard for diphtheria antitoxin (equine)	82
8.1.4	Proposed First WHO international standards for antibodies against human papillomavirus types 6, 11, 31, 33, 45, 52 and 58	83
8.1.5	Proposed Second WHO International Standard for hepatitis A vaccine	84
8.1.6	Proposed WHO international standards for oral poliomyelitis vaccine	85
<b>Annex 1</b>		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological substances used in medicine	87
<b>Annex 2</b>		
	Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs)	93
<b>Annex 3</b>		
	Guidelines on management of blood and blood components as essential medicines	129
<b>Annex 4</b>		
	Guidelines on estimation of residual risk of HIV, HBV or HCV infections via cellular blood components and plasma	163
<b>Annex 5</b>		
	Guidelines for the production, control and regulation of snake antivenom immunoglobulins	
	Replacement of Annex 2 of WHO Technical Report Series, No. 964	197
<b>Annex 6</b>		
	WHO manual for the preparation of secondary reference materials for in vitro diagnostic assays designed for infectious disease nucleic acid or antigen detection: calibration to WHO International Standards	389
<b>Annex 7</b>		
	Guidelines on regulatory preparedness for provision of marketing authorization of human pandemic influenza vaccines in non-vaccine-producing countries	457
<b>Annex 8</b>		

预览已结束，完整报告链接为

<https://www.yunbaogao.cn/report/index/repo>